<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Neuromuscular Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Neuromuscular Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Нервно-мышечные болезни</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-8721</issn><issn publication-format="electronic">2413-0443</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">203</article-id><article-id pub-id-type="doi">10.17650/2222-8721-2017-7-2-10-20</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>LECTURES AND REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЛЕКЦИИ И ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Glucocorticoid induced osteoporosis in neurological patients: prevention and treatment</article-title><trans-title-group xml:lang="ru"><trans-title>Глюкокортикоидиндуцированный остеопороз у неврологических больных: мероприятия по профилактике и лечению</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Antonova</surname><given-names>K. V.</given-names></name><name xml:lang="ru"><surname>Антонова</surname><given-names>К. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>belovanv22@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Suponeva</surname><given-names>N. A.</given-names></name><name xml:lang="ru"><surname>Супонева</surname><given-names>Н. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>belovanv22@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shcherbakova</surname><given-names>N. I.</given-names></name><name xml:lang="ru"><surname>Щербакова</surname><given-names>Н. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>belovanv22@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Grishina</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Гришина</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>belovanv22@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Belova</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Белова</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>belovanv22@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kononova</surname><given-names>L. V.</given-names></name><name xml:lang="ru"><surname>Кононова</surname><given-names>Л. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>belovanv22@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Center of Neurology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научный центр неврологии»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-09-27" publication-format="electronic"><day>27</day><month>09</month><year>2017</year></pub-date><volume>7</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>10</fpage><lpage>20</lpage><history><date date-type="received" iso-8601-date="2017-09-28"><day>28</day><month>09</month><year>2017</year></date><date date-type="accepted" iso-8601-date="2017-09-28"><day>28</day><month>09</month><year>2017</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Antonova K.V., Suponeva N.A., Shcherbakova N.I., Grishina D.A., Belova N.V., Kononova L.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, Антонова К.В., Супонева Н.А., Щербакова Н.И., Гришина Д.А., Белова Н.В., Кононова Л.В.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Antonova K.V., Suponeva N.A., Shcherbakova N.I., Grishina D.A., Belova N.V., Kononova L.V.</copyright-holder><copyright-holder xml:lang="ru">Антонова К.В., Супонева Н.А., Щербакова Н.И., Гришина Д.А., Белова Н.В., Кононова Л.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://nmb.abvpress.ru/jour/article/view/203">https://nmb.abvpress.ru/jour/article/view/203</self-uri><abstract xml:lang="en"><p>Glucocorticoids (GCs) are often prescribed for neurologic patients. Autoimmune diseases of central and peripheral nervous system, neuromuscular disorders are associated with disability and life-threatening complications, and require long-term high-dosage administration of GCs. GC-therapy is a crucial decision to be made by a neurologist in collaboration with a patient, and requires strict observance of clear guidelines on the prevention, diagnosis and treatment of possible complications. One of the most frequent complications of GCs is osteoporosis. According to the Russian and international guidelines, all the patients must undergo preliminary and follow-up laboratory and instrumental examination, as well as administration of calcium and vitamin D during the whole period of GC-therapy. In case of a high fracture risk or if osteoporosis is diagnosed, antiresorptive therapy is indicated.</p></abstract><trans-abstract xml:lang="ru"><p>В практике невролога регулярно возникает необходимость в назначении глюкокортикостероидов (ГКС). Аутоиммунная патология центральной и периферической нервной и нервно-мышечной систем часто сопряжена с выраженной инвалидизацией и жизнеугрожающими осложнениями, что определяет необходимость применения ГКС в высоких дозах в течение длительного периода времени. Назначение ГКС – ответственное решение, которое принимается неврологом совместно с пациентом и требует неукоснительного соблюдения четких рекомендаций по профилактике, диагностике и лечению возможных осложнений. Одним из частых осложнений ГКС является глюкокортикоидиндуцированный остеопороз. Согласно отечественным и зарубежным рекомендациям всем пациентам необходимо предварительное и динамическое лабораторное и инструментальное обследование, а также применение препаратов кальция и витамина D на весь период терапии ГКС. В случае высокого риска возникновения перелома или при выявлении остеопороза показана антирезорбтивная терапия.</p><p> </p><p> </p></trans-abstract><kwd-group xml:lang="en"><kwd>glucocorticosteroids</kwd><kwd>osteoporosis</kwd><kwd>osteoporotic fracture</kwd><kwd>bone mineral density</kwd><kwd>vitamin D</kwd><kwd>calcium</kwd><kwd>multiple sclerosis</kwd><kwd>myasthenia</kwd><kwd>chronic inflammatory demyelinating polyradiculoneuropathy</kwd><kwd>polymyositis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>глюкокортикостероиды</kwd><kwd>остеопороз</kwd><kwd>остеопоротический перелом</kwd><kwd>минеральная плотность кости</kwd><kwd>витамин D</kwd><kwd>кальций</kwd><kwd>рассеянный склероз</kwd><kwd>миастения</kwd><kwd>хроническая воспалительная демиелинизирующая полинейропатия</kwd><kwd>полимиозит</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Супонева Н.А., Наумова Е.С., Гнедовская Е.В. Хроническая воспалительная демиелинизирующая полинейропатия у взрослых: принципы диагностики и терапия первой линии. Нервно- мышечные болезни 2016;6(1):44–53. [Suponevа N.А., Naumovа E.S., Gnedovskaya E.V. Chronic inflammatory demyelinating polyneuropathy in adults: diagnostic approaches and first line therapy. Nervno-myshechnye bolezni = Neuromuscular Diseases 2016;6(1): 44–53. (In Russ.)]. DOI: 10.17650/2222-8721-2016-6-1-44-53.</mixed-citation><mixed-citation xml:lang="ru">Супонева Н.А., Наумова Е.С., Гнедовская Е.В. Хроническая воспалительная демиелинизирующая полинейропатия у взрослых: принципы диагностики и терапия первой линии. Нервно- мышечные болезни 2016;6(1):44–53. [Suponevа N.А., Naumovа E.S., Gnedovskaya E.V. Chronic inflammatory demyelinating polyneuropathy in adults: diagnostic approaches and first line therapy. Nervno-myshechnye bolezni = Neuromuscular Diseases 2016;6(1): 44–53. (In Russ.)]. DOI: 10.17650/2222-8721-2016-6-1-44-53.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Пирадов М.А., Супонева Н.А. Аутоиммунные заболевания нервной системы: состояние проблемы и перспективы. Вестник Российской академии медицинских наук 2015;70(2):183–7. [Piradov M.A., Suponeva N.A. Autoimmune diseases of the nervous system: problem statement and prospects. Vestnik Rossiyskoy akademii meditsinskikh nauk = Bulletin of the Russian Academy of Medical Sciences 2015;70(2):183–7. (In Russ.)]. DOI: 10.15690/vramn.v70i2.1311.</mixed-citation><mixed-citation xml:lang="ru">Пирадов М.А., Супонева Н.А. Аутоиммунные заболевания нервной системы: состояние проблемы и перспективы. Вестник Российской академии медицинских наук 2015;70(2):183–7. [Piradov M.A., Suponeva N.A. Autoimmune diseases of the nervous system: problem statement and prospects. Vestnik Rossiyskoy akademii meditsinskikh nauk = Bulletin of the Russian Academy of Medical Sciences 2015;70(2):183–7. (In Russ.)]. DOI: 10.15690/vramn.v70i2.1311.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Гинзберг М.А., Варламова А.Ю., Рыжко В.В. и др. Клинико-нейрофизиологическое исследование хронической демиелинизирующей полиневропатии, ассоциированной с моноклональной секрецией. Медицинский совет 2015;(10):93–9. [Ginzberg M.A., Varlamova A.Yu., Ryzhko V.V. et al. Clinical and neurophysiological studies of chronic demyelinating polyneuropathy associated with monoclonal secretion. Meditsinskiy sovet = Medical Council 2015;(10):93–9. (In Russ.)]. DOI: 10.21518/2079-701X-2015-10-93-99.</mixed-citation><mixed-citation xml:lang="ru">Гинзберг М.А., Варламова А.Ю., Рыжко В.В. и др. Клинико-нейрофизиологическое исследование хронической демиелинизирующей полиневропатии, ассоциированной с моноклональной секрецией. Медицинский совет 2015;(10):93–9. [Ginzberg M.A., Varlamova A.Yu., Ryzhko V.V. et al. Clinical and neurophysiological studies of chronic demyelinating polyneuropathy associated with monoclonal secretion. Meditsinskiy sovet = Medical Council 2015;(10):93–9. (In Russ.)]. DOI: 10.21518/2079-701X-2015-10-93-99.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Шнайдер Н.А., Дыхно Ю.А., Ежикова В.В. Структура и частота встречаемости паранеопластического неврологического синдрома при онкопатологии органов грудной клетки. Сибирский онкологический журнал 2012;(1):63–70. [Shnayder N.A., Dykhno Yu.A., Ezhikova V.V. Structure and incidence of paraneoplastic syndrome in thoracic cancer. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2012;(1):63–70.</mixed-citation><mixed-citation xml:lang="ru">Шнайдер Н.А., Дыхно Ю.А., Ежикова В.В. Структура и частота встречаемости паранеопластического неврологического синдрома при онкопатологии органов грудной клетки. Сибирский онкологический журнал 2012;(1):63–70. [Shnayder N.A., Dykhno Yu.A., Ezhikova V.V. Structure and incidence of paraneoplastic syndrome in thoracic cancer. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2012;(1):63–70.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><mixed-citation>(In Russ.)].</mixed-citation></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">5. Шнайдер Н.А., Дыхно Ю.А., Ежикова В.В. Клиническая гетерогенность паранеопластического неврологического синдрома. Сибирский онкологический журнал 2011;(3):82–90. [Shnayder N.A., Dykhno Yu.A., Ezhikova V.V. Clinical heterogeneity</mixed-citation><mixed-citation xml:lang="ru">Шнайдер Н.А., Дыхно Ю.А., Ежикова В.В. Клиническая гетерогенность паранеопластического неврологического синдрома. Сибирский онкологический журнал 2011;(3):82–90. [Shnayder N.A., Dykhno Yu.A., Ezhikova V.V. Clinical heterogeneity</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><mixed-citation>of paraneoplastic neurological syndrome. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2011;(3):82–90. (In Russ.)].</mixed-citation></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">6. Rodriguez J.M., Monsalves-Alvarez M., Henriquez S. et al. Glucocorticoid resistance in chronic diseases. Steroids 2016;115:182–92. DOI: 10.1016/j.steroids.2016.09.010. PMID: 27643454.</mixed-citation><mixed-citation xml:lang="ru">Rodriguez J.M., Monsalves-Alvarez M., Henriquez S. et al. Glucocorticoid resistance in chronic diseases. Steroids 2016;115:182–92. DOI: 10.1016/j.steroids.2016.09.010. PMID: 27643454.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">7. Orcel P. Prise en charge de l’osteoporosecortisonique. Presse Med 2006;35(10):1571–7. DOI: 10.1016/s0755-4982(06)74853-9. PMID: 17028523.</mixed-citation><mixed-citation xml:lang="ru">Orcel P. Prise en charge de l’osteoporosecortisonique. Presse Med 2006;35(10):1571–7. DOI: 10.1016/s0755-4982(06)74853-9. PMID: 17028523.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">8. Walsh L.J., Wong C.A., Pringle M., Tattersfield A.E. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996;313(7053):344–6. DOI: 10.1136/bmj.313.7053.344. PMID: 8760745.</mixed-citation><mixed-citation xml:lang="ru">Walsh L.J., Wong C.A., Pringle M., Tattersfield A.E. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996;313(7053):344–6. DOI: 10.1136/bmj.313.7053.344. PMID: 8760745.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">9. Carr A.S., Cardwell C.R., McCarron P.O., McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 2010;10:46. DOI: 10.1186/1471-2377-10-46. PMID: 20565885.</mixed-citation><mixed-citation xml:lang="ru">Carr A.S., Cardwell C.R., McCarron P.O., McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 2010;10:46. DOI: 10.1186/1471-2377-10-46. PMID: 20565885.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">10. Melcon M.O., Correale J., Melcon C.M. Is it time for a new global classification of multiple sclerosis? J Neurol Sci 2014;344(1–2):171–81. DOI: 10.1016/j.jns.2014.06.051. PMID: 25062946.</mixed-citation><mixed-citation xml:lang="ru">Melcon M.O., Correale J., Melcon C.M. Is it time for a new global classification of multiple sclerosis? J Neurol Sci 2014;344(1–2):171–81. DOI: 10.1016/j.jns.2014.06.051. PMID: 25062946.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">11. Hanewinckel R., Ikram M.A., van Doorn P.A. Peripheral neuropathies. Handb Clin Neurol 2016;138:263–82. DOI: 10.1016/B978-0-12-802973-2.00015-X. PMID: 27637963.</mixed-citation><mixed-citation xml:lang="ru">Hanewinckel R., Ikram M.A., van Doorn P.A. Peripheral neuropathies. Handb Clin Neurol 2016;138:263–82. DOI: 10.1016/B978-0-12-802973-2.00015-X. PMID: 27637963.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">12. Шнайдер Н.А., Кантимирова Е.А. Эпидемиологическая и клиническая характеристика отдельных форм полиневропатий (на примере ЗАТО Железногорск Красноярского края). Нервно-мышечные болезни 2011;(1):34–41. [Shnayder N.A., Kantimirova E.A. The epidemiological and clinical characteristics of the separate forms of polyneuropathies (example Zheleznogorsk city of Krasnoyarsk region). Nervnomyshechnie bolezni = Neuromuscular Diseases 2011;(1):34–41. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Шнайдер Н.А., Кантимирова Е.А. Эпидемиологическая и клиническая характеристика отдельных форм полиневропатий (на примере ЗАТО Железногорск Красноярского края). Нервно-мышечные болезни 2011;(1):34–41. [Shnayder N.A., Kantimirova E.A. The epidemiological and clinical characteristics of the separate forms of polyneuropathies (example Zheleznogorsk city of Krasnoyarsk region). Nervnomyshechnie bolezni = Neuromuscular Diseases 2011;(1):34–41. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">13. Супонева Н., Павлов Э. Диагностика и базовая терапия хронических полиневропатий. Врач 2009;(9):43–4. [Suponeva N., Pavlov E. Diagnosis and basic therapy of chronic polyneuropathies. Vrach = Doctor 2009;(9):43–4. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Супонева Н., Павлов Э. Диагностика и базовая терапия хронических полиневропатий. Врач 2009;(9):43–4. [Suponeva N., Pavlov E. Diagnosis and basic therapy of chronic polyneuropathies. Vrach = Doctor 2009;(9):43–4. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">14. Вышковский Г.Л. Регистр лекарственных средств России. РЛС. Энциклопедия лекарств. М.: РЛС-МЕДИА, 2009. 1296 с. [Vyshkovskiy G.L. Registry of medicinal product of Russia. RMP. Drug encyclopedia. Moscow: RLS-MEDIA, 2009. 1296 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Вышковский Г.Л. Регистр лекарственных средств России. РЛС. Энциклопедия лекарств. М.: РЛС-МЕДИА, 2009. 1296 с. [Vyshkovskiy G.L. Registry of medicinal product of Russia. RMP. Drug encyclopedia. Moscow: RLS-MEDIA, 2009. 1296 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">15. Liu D., Ahmet A., Ward L. et al. A practical guide to the monitoring</mixed-citation><mixed-citation xml:lang="ru">Liu D., Ahmet A., Ward L. et al. A practical guide to the monitoring</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><mixed-citation>and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013;9(1):30. DOI: 10.1186/1710-1492-9-30. PMID: 23947590.</mixed-citation></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">16. Briot K., Roux C. Glucocorticoid-induced osteoporosis. RMD Open 2015;1(1):e000014. DOI: 10.1136/rmdopen-2014-000014. PMID: 26509049.</mixed-citation><mixed-citation xml:lang="ru">Briot K., Roux C. Glucocorticoid-induced osteoporosis. RMD Open 2015;1(1):e000014. DOI: 10.1136/rmdopen-2014-000014. PMID: 26509049.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">17. Завалишин И.А., Пирадов М.А., Бойко А.Н. Аутоиммунные заболевания в неврологии. Том 2. М.: Региональная общественная организация инвалидов «Здоровье человека», 2014. 192 с. [Zavalishin I.A., Piradov M.A., Boyko A.N. Autoimmune diseases</mixed-citation><mixed-citation xml:lang="ru">Завалишин И.А., Пирадов М.А., Бойко А.Н. Аутоиммунные заболевания в неврологии. Том 2. М.: Региональная общественная организация инвалидов «Здоровье человека», 2014. 192 с. [Zavalishin I.A., Piradov M.A., Boyko A.N. Autoimmune diseases</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><mixed-citation>in neurology. Vol. 2. Moscow: Regional’naya obshchestvennaya organizatsiya invalidov “Zdorov’e cheloveka”, 2014. 192 p. (In Russ.)].</mixed-citation></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">18. van Staa T.P. The pathogenesis, epidemiology and management</mixed-citation><mixed-citation xml:lang="ru">van Staa T.P. The pathogenesis, epidemiology and management</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><mixed-citation>of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006;79(3):129–37. DOI: 10.1007/s00223-006-0019-1. PMID: 16969593.</mixed-citation></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">19. van Staa T.P., Leufkens H.G., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13(10):777–87. DOI: 10.1007/s001980200108. PMID: 12378366.</mixed-citation><mixed-citation xml:lang="ru">van Staa T.P., Leufkens H.G., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13(10):777–87. DOI: 10.1007/s001980200108. PMID: 12378366.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">20. Steinbuch M., Youket T.E., Cohen S. Oral glucocorticoid use is associated with an increased risk of fractures. Osteoporos Int 2004;15(4):323–8. DOI: 10.1007/s00198-003-1548-3. PMID: 14762652.</mixed-citation><mixed-citation xml:lang="ru">Steinbuch M., Youket T.E., Cohen S. Oral glucocorticoid use is associated with an increased risk of fractures. Osteoporos Int 2004;15(4):323–8. DOI: 10.1007/s00198-003-1548-3. PMID: 14762652.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">21. Konno S., Suzuki S., Masuda M. et al. Association between glucocorticoid-induced osteoporosis and myasthenia gravis: a cross-sectional study. PLoS One 2015;10(5):e0126579. DOI: 10.1371/journal.pone.0126579. PMID: 25965387.</mixed-citation><mixed-citation xml:lang="ru">Konno S., Suzuki S., Masuda M. et al. Association between glucocorticoid-induced osteoporosis and myasthenia gravis: a cross-sectional study. PLoS One 2015;10(5):e0126579. DOI: 10.1371/journal.pone.0126579. PMID: 25965387.</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">22. Stellato C. Post-transcriptional and nongenomic effects of glucocorticoids. Proc Am Thorac Soc 2004;1(3):255–63. DOI: 10.1513/pats.200402-015MS. PMID: 16113443.</mixed-citation><mixed-citation xml:lang="ru">Stellato C. Post-transcriptional and nongenomic effects of glucocorticoids. Proc Am Thorac Soc 2004;1(3):255–63. DOI: 10.1513/pats.200402-015MS. PMID: 16113443.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">23. Дедов И.И. Эндокринология. М.: ГЭОТАР-Медиа, 2009. 432 с. [Dedov I.I. Endocrinology. Moscow: GEOTAR-Media, 2009. 432 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Дедов И.И. Эндокринология. М.: ГЭОТАР-Медиа, 2009. 432 с. [Dedov I.I. Endocrinology. Moscow: GEOTAR-Media, 2009. 432 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">24. Dimachkie M.M., Barohn R.J. Chronic inflammatory demyelinating polyneuropathy. Curr Treat Option Neurolo 2013;15(3):350–66. DOI: 10.1007/s11940-013-0229-6.</mixed-citation><mixed-citation xml:lang="ru">Dimachkie M.M., Barohn R.J. Chronic inflammatory demyelinating polyneuropathy. Curr Treat Option Neurolo 2013;15(3):350–66. DOI: 10.1007/s11940-013-0229-6.</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">25. Yeh J.H., Chen H.J., Chen Y.K. et al. Increased risk of osteoporosis in patients with myasthenia gravis: a population-based cohort study. Neurology 2014;83(12):1075–9. DOI: 10.1212/WNL.0000000000000804. PMID: 25122205.</mixed-citation><mixed-citation xml:lang="ru">Yeh J.H., Chen H.J., Chen Y.K. et al. Increased risk of osteoporosis in patients with myasthenia gravis: a population-based cohort study. Neurology 2014;83(12):1075–9. DOI: 10.1212/WNL.0000000000000804. PMID: 25122205.</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">26. Pouwels S., de Boer A., Javaid M.K. et al. Fracture rate in patients with myasthenia gravis: the general practice research database. Osteoporos Int 2013;24(2):467–76. DOI: 10.1007/s00198-012-1970-5. PMID: 22531999.</mixed-citation><mixed-citation xml:lang="ru">Pouwels S., de Boer A., Javaid M.K. et al. Fracture rate in patients with myasthenia gravis: the general practice research database. Osteoporos Int 2013;24(2):467–76. DOI: 10.1007/s00198-012-1970-5. PMID: 22531999.</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">27. Huang Z., Qi Y., Du S. et al. BMI levels with MS Bone mineral density levels in adults with multiple sclerosis: a meta-analysis. Int J Neurosci 2015;125(12):904–12. DOI: 10.3109/00207454.2014.988332. PMID: 25405534.</mixed-citation><mixed-citation xml:lang="ru">Huang Z., Qi Y., Du S. et al. BMI levels with MS Bone mineral density levels in adults with multiple sclerosis: a meta-analysis. Int J Neurosci 2015;125(12):904–12. DOI: 10.3109/00207454.2014.988332. PMID: 25405534.</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">28. Dabbaghmanesh M.H., Yousefipour G.A. Bone loss with multiple sclerosis: effect of glucocorticoid use and functional status. Iran Red Crescent Med J 2011; 13(1):9–14. DOI: 10.2147/IJGM.S22255. PMID: 22946013.</mixed-citation><mixed-citation xml:lang="ru">Dabbaghmanesh M.H., Yousefipour G.A. Bone loss with multiple sclerosis: effect of glucocorticoid use and functional status. Iran Red Crescent Med J 2011; 13(1):9–14. DOI: 10.2147/IJGM.S22255. PMID: 22946013.</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">29. Kępczyńska K., Zajda M., Lewandowski Z. et al. Bone metabolism and vitamin D status in patients with multiple sclerosis. Neurol Neurochir Pol 2016;50(4):251–7. DOI: 10.1016/j.pjnns.2016.04.010. PMID: 27375138.</mixed-citation><mixed-citation xml:lang="ru">Kępczyńska K., Zajda M., Lewandowski Z. et al. Bone metabolism and vitamin D status in patients with multiple sclerosis. Neurol Neurochir Pol 2016;50(4):251–7. DOI: 10.1016/j.pjnns.2016.04.010. PMID: 27375138.</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">30. Алексеева Л.И., Баранова И.А., Белова К.Ю. и др. Клинические рекомендации по профилактике и ведению больных с остеопорозом. Российская ассоциация по остеопорозу. Ярославль: ИПК «Литера», 2016. 24 с. [Alekseeva L.I., Baranova I.A., Belova K.Yu. et al. Clinical guidelines on prevention and management in patients with osteoporosis. Russian Association for Osteoporosis. Yaroslavl’: IPK “Litera”, 2016. 24 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Алексеева Л.И., Баранова И.А., Белова К.Ю. и др. Клинические рекомендации по профилактике и ведению больных с остеопорозом. Российская ассоциация по остеопорозу. Ярославль: ИПК «Литера», 2016. 24 с. [Alekseeva L.I., Baranova I.A., Belova K.Yu. et al. Clinical guidelines on prevention and management in patients with osteoporosis. Russian Association for Osteoporosis. Yaroslavl’: IPK “Litera”, 2016. 24 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">31. Shaker J.L., Lukert B.P. Osteoporosis associated with excess glucocorticoids. Endocrinol Metab Clin North Am 2005;34(2):341–56. DOI: 10.1016/j.ecl.2005.01.014. PMID: 15850846.</mixed-citation><mixed-citation xml:lang="ru">Shaker J.L., Lukert B.P. Osteoporosis associated with excess glucocorticoids. Endocrinol Metab Clin North Am 2005;34(2):341–56. DOI: 10.1016/j.ecl.2005.01.014. PMID: 15850846.</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">32. Kanis J.A., Johansson H., Oden A. et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19(6):893–9. DOI: 10.1359/jbmr.040134. PMID: 15125788.</mixed-citation><mixed-citation xml:lang="ru">Kanis J.A., Johansson H., Oden A. et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19(6):893–9. DOI: 10.1359/jbmr.040134. PMID: 15125788.</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">33. Luengo M., Picado C., Del Rio L. et al. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 1991;46(11):803–6. DOI: 10.1136/thx.46.11.803. PMID: 1771602.</mixed-citation><mixed-citation xml:lang="ru">Luengo M., Picado C., Del Rio L. et al. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 1991;46(11):803–6. DOI: 10.1136/thx.46.11.803. PMID: 1771602.</mixed-citation></citation-alternatives></ref><ref id="B39"><label>39.</label><citation-alternatives><mixed-citation xml:lang="en">34. Johnell O., de Laet C., Johansson H. et al. Oral corticosteroids increase fracture risk independently of BMD. Osteoporos Int 2002;13:14.</mixed-citation><mixed-citation xml:lang="ru">Johnell O., de Laet C., Johansson H. et al. Oral corticosteroids increase fracture risk independently of BMD. Osteoporos Int 2002;13:14.</mixed-citation></citation-alternatives></ref><ref id="B40"><label>40.</label><citation-alternatives><mixed-citation xml:lang="en">35. van Staa T.P., Leufkens H.G., Abenhaim L. et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology 2000;39(12):1383–9. DOI: 10.1093/rheumatology/39.12.1383. PMID: 11136882.</mixed-citation><mixed-citation xml:lang="ru">van Staa T.P., Leufkens H.G., Abenhaim L. et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology 2000;39(12):1383–9. DOI: 10.1093/rheumatology/39.12.1383. PMID: 11136882.</mixed-citation></citation-alternatives></ref><ref id="B41"><label>41.</label><citation-alternatives><mixed-citation xml:lang="en">36. Макдермотт М.Т. Секреты эндокринологии. М.: Бином, 2015. 584 с. [McDermott M.T. Endocrine Secrets. Moscow: Binom, 2015. 584 p. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Макдермотт М.Т. Секреты эндокринологии. М.: Бином, 2015. 584 с. [McDermott M.T. Endocrine Secrets. Moscow: Binom, 2015. 584 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B42"><label>42.</label><citation-alternatives><mixed-citation xml:lang="en">37. Ilias I., Ghayee H. Glucocorticoid-induced osteoporosis. Eds.: L.J. de Groot, G. Chrousos, K. Dungan et al. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc., 2000. Available at: https://www.ncbi.nlm.nih.gov/books/ NBK278968/.</mixed-citation><mixed-citation xml:lang="ru">Ilias I., Ghayee H. Glucocorticoid-induced osteoporosis. Eds.: L.J. de Groot, G. Chrousos, K. Dungan et al. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc., 2000. Available at: https://www.ncbi.nlm.nih.gov/books/ NBK278968/.</mixed-citation></citation-alternatives></ref><ref id="B43"><label>43.</label><citation-alternatives><mixed-citation xml:lang="en">38. FRAX. Available at: http://www.shef.ac.uk/FRAX/index.aspx?lang=rs.</mixed-citation><mixed-citation xml:lang="ru">FRAX. Available at: http://www.shef.ac.uk/FRAX/index.aspx?lang=rs.</mixed-citation></citation-alternatives></ref><ref id="B44"><label>44.</label><citation-alternatives><mixed-citation xml:lang="en">39. Leib E.S., Saag K.G., Adachi J.D. et al. The impact of the use of glucocorticoids on the estimate by FRAX of the 10 year risk of fracture. J Clin Densitom 2011;14(3):212–9.</mixed-citation><mixed-citation xml:lang="ru">Leib E.S., Saag K.G., Adachi J.D. et al. The impact of the use of glucocorticoids on the estimate by FRAX of the 10 year risk of fracture. J Clin Densitom 2011;14(3):212–9.</mixed-citation></citation-alternatives></ref><ref id="B45"><label>45.</label><mixed-citation>DOI: 10.1016/j.jocd.2011.05.014. PMID: 21810527.</mixed-citation></ref><ref id="B46"><label>46.</label><citation-alternatives><mixed-citation xml:lang="en">40. Kanis J.A., Johansson H., Oden A., McCloskey E.V. Guidance for the adjustment of FRAX according to the dose</mixed-citation><mixed-citation xml:lang="ru">Kanis J.A., Johansson H., Oden A., McCloskey E.V. Guidance for the adjustment of FRAX according to the dose</mixed-citation></citation-alternatives></ref><ref id="B47"><label>47.</label><mixed-citation>of glucocorticoids. Osteoporos Int 2011;22(3):809–16. DOI: 10.1007/s00198-010-1524-7. PMID: 21229233.</mixed-citation></ref><ref id="B48"><label>48.</label><citation-alternatives><mixed-citation xml:lang="en">41. Федеральные клинические рекомендации. Дефицит витамина D у взрослых: диагностика, лечение и профилактика. M., 2015. 75 с. [Federal clinical guidelines. Vitamin D deficiency in adults: diagnosis, treatment, and prevention. Moscow, 2015. 75 p.</mixed-citation><mixed-citation xml:lang="ru">Федеральные клинические рекомендации. Дефицит витамина D у взрослых: диагностика, лечение и профилактика. M., 2015. 75 с. [Federal clinical guidelines. Vitamin D deficiency in adults: diagnosis, treatment, and prevention. Moscow, 2015. 75 p.</mixed-citation></citation-alternatives></ref><ref id="B49"><label>49.</label><mixed-citation>(In Russ.)].</mixed-citation></ref><ref id="B50"><label>50.</label><citation-alternatives><mixed-citation xml:lang="en">42. Saag K.G., Emkey R., Schnitzer T.J. et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1999;339(5):292–9. DOI: 10.1056/NEJM199807303390502. PMID: 9682041.</mixed-citation><mixed-citation xml:lang="ru">Saag K.G., Emkey R., Schnitzer T.J. et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1999;339(5):292–9. DOI: 10.1056/NEJM199807303390502. PMID: 9682041.</mixed-citation></citation-alternatives></ref><ref id="B51"><label>51.</label><citation-alternatives><mixed-citation xml:lang="en">43. Adachi J.D., Saag K.G., Delmas P.D. et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo controlled extension trial. Arthritis Rheum 2001;44(1):202–11. DOI: 10.1002/1529-0131(200101) 44:13.0.CO;2-W. PMID: 11212161.</mixed-citation><mixed-citation xml:lang="ru">Adachi J.D., Saag K.G., Delmas P.D. et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo controlled extension trial. Arthritis Rheum 2001;44(1):202–11. DOI: 10.1002/1529-0131(200101) 44:13.0.CO;2-W. PMID: 11212161.</mixed-citation></citation-alternatives></ref><ref id="B52"><label>52.</label><citation-alternatives><mixed-citation xml:lang="en">44. Cohen S., Levy R.M., Keller M. et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42(11):2309–18. DOI: 10.1002/1529-0131(199911) 42:11 3.0.CO;2-K. PMID: 10555025.</mixed-citation><mixed-citation xml:lang="ru">Cohen S., Levy R.M., Keller M. et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42(11):2309–18. DOI: 10.1002/1529-0131(199911) 42:11 3.0.CO;2-K. PMID: 10555025.</mixed-citation></citation-alternatives></ref><ref id="B53"><label>53.</label><citation-alternatives><mixed-citation xml:lang="en">45. Wallach S., Cohen S., Reid D.M. et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67(4):277–85. DOI: 10.1007/s002230001146. PMID: 11000340.</mixed-citation><mixed-citation xml:lang="ru">Wallach S., Cohen S., Reid D.M. et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67(4):277–85. DOI: 10.1007/s002230001146. PMID: 11000340.</mixed-citation></citation-alternatives></ref><ref id="B54"><label>54.</label><citation-alternatives><mixed-citation xml:lang="en">46. Reid D.M., Devogelaer J.P., Saag K. et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009;373(9671):1253–63. DOI: 10.1016/S0140-6736(09)60250-6. PMID: 19362675.</mixed-citation><mixed-citation xml:lang="ru">Reid D.M., Devogelaer J.P., Saag K. et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009;373(9671):1253–63. DOI: 10.1016/S0140-6736(09)60250-6. PMID: 19362675.</mixed-citation></citation-alternatives></ref><ref id="B55"><label>55.</label><citation-alternatives><mixed-citation xml:lang="en">47. Dore R.K., Cohen S.B., Lane N.E. et al. Effects of denosumab one bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010;69:872–5. DOI: 10.1136/ard.2009.112920.</mixed-citation><mixed-citation xml:lang="ru">Dore R.K., Cohen S.B., Lane N.E. et al. Effects of denosumab one bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010;69:872–5. DOI: 10.1136/ard.2009.112920.</mixed-citation></citation-alternatives></ref><ref id="B56"><label>56.</label><citation-alternatives><mixed-citation xml:lang="en">48. Saag K.G., Shane E., Boonen S. et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357(20):2028–39. DOI: 10.1056/NEJMoa071408. PMID: 18003959.</mixed-citation><mixed-citation xml:lang="ru">Saag K.G., Shane E., Boonen S. et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357(20):2028–39. DOI: 10.1056/NEJMoa071408. PMID: 18003959.</mixed-citation></citation-alternatives></ref><ref id="B57"><label>57.</label><citation-alternatives><mixed-citation xml:lang="en">49. Saag K.G., Zanchetta J.R., Devogelaer J.P. et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009;60(11):3346–55. DOI: 10.1002/art.24879. PMID: 19877063.</mixed-citation><mixed-citation xml:lang="ru">Saag K.G., Zanchetta J.R., Devogelaer J.P. et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009;60(11):3346–55. DOI: 10.1002/art.24879. PMID: 19877063.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
